GEMPHARMATECH USA

Company Overview

GemPharmatech is a leading contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. Our company is steadfast in its commitment to providing cutting-edge and novel solutions to researchers in their pursuit of scientific exploration and pharmaceutical development. At GemPharmatech, we specialize in the development of animal models utilizing advanced gene-editing technologies, and we have an extensive library of KO/cKO mice, humanized mice, immunodeficient mice, and germ-free mice. We offer a wide range of preclinical services, including mouse model customization, pharmacology services such as drug efficacy evaluation and mouse phenotyping, CRISPR/Cas9 gene editing, cryopreservation, and customized breeding.

Our ultimate goal is to accelerate scientific advancement and pharmaceutical development by supporting our clients with the most innovative tools and services. We have amassed one of the broadest collections of mouse models in the world, which have garnered immense popularity among scientists globally. By partnering with GemPharmatech, our clients benefit from having access to a comprehensive range of research tools and services to aid them in their research endeavors and promote scientific discovery. GemPharmatech is committed to pushing the boundaries of preclinical research and assisting our customers in achieving their research ambitions. We take great pride in providing exceptional customer service and are dedicated to providing our clients with the highest-quality research solutions.

Leadership Team

• 

  Mark W. Moore, PhD

  CHIEF EXECUTIVE OFFICER

  Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.

• 

  Zhiying Li, PhD

  DIRECTOR, LIFE SCIENCE AND TECHNOLOGY

  Zhiying is a trained neuroscientist with a doctoral degree from Harvard University. She conducted her postdoctoral research at Rockefeller University. Prior to joining GemPharmatech, she worked at Taconic Biosciences, providing scientific support to both commercial products and scientific services. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.

• 

  Santi Suryani Chen, PhD

  ASSOCIATE DIRECTOR, IMMUNOLOGY AND ONCOLOGY

  Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.